This AD-related increase is masked in APOE4-carrying AD patients either due to higher plasma IAPPo levels, increased APOE4–IAPP binding, or reduced production of specifically IAPPO-IgA due to epitope masking. This evidence concerns the gene APOE and Alzheimer disease.